Waldencast Acquisition Corp. Class A WALD 深 滬
等待開盤 12-25 09:30:00 美东时间
1.99
+0.090
+4.74%
華盛通- 最 高2.03
- 今 開1.90
- 成交量 6.58万股
- 最 低 1.90
- 昨 收 1.90
- 總市值 2.45亿
- 52周最高 4.10
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 1.4801
- 委 比 58.10%
- 總股本 1.23亿
- 歷史最高 12.10
- 量 比 1.60
- 振 幅 6.84%
- 歷史最低 1.4801
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
Canaccord Genuity Maintains Buy on Waldencast, Lowers Price Target to $4
Canaccord Genuity analyst Susan Anderson maintains Waldencast (NASDAQ:WALD) with a Buy and lowers the price target from $5 to $4.
11-26 01:51
Waldencast H1 Adj. EPS $(0.16) Misses $(0.07) Estimate, Sales $132.274M Beat $67.692M Estimate
Waldencast (NASDAQ:WALD) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.07) by 122.22 percent. This is a 77.78 percent decrease over losses of $(0.09) per share from the
11-25 06:41
Waldencast shares are trading lower. The company reported Q2 financial results.
Waldencast shares are trading lower. The company reported Q2 financial results.
11-24 22:13
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining ar...
11-24 21:08
Waldencast Plc Sells Its Rights To The "Obagi" Trademark In Japan To Rohto Pharmaceutical For $82.5M
Waldencast plc, (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the "Obagi" trademark in Japan to Rohto Pharmaceutical Co.,
11-15 06:09
Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
Obagi Medical introduces Nu-Cil® BioStim™ Scalp Serum, a next-generation product designed to promote fuller, denser hair. Clinically proven to reduce dry, fallen hair by 74% in three months, the serum contains Biotin, Amino Acids, Peptides, and 18 essential Nutrients, B Vitamins, and Phytoactives. It addresses hair loss concerns and enhances overall hair vitality. Priced at $125, it's available on Obagi.com.
10-08 12:00
Waldencast Says FDA Approves Obagi Saypha MagIQ Injectable Hyaluronic Acid Gel
Waldencast plc (NASDAQ:WALD), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration ("FDA") has approved Obagi® saypha® MagIQ™ injectable
09-10 18:50
Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
Waldencast's Obagi Medical brand has received FDA approval for Obagi® saypha® MagIQ™, its first HA dermal filler, marking entry into the U.S. market and doubling Obagi's addressable market to $4.2B by 2029. Planned U.S. launch in 2026, the product leverages Obagi's skincare network for enhanced value. Developed by Croma-Pharma, it uses proprietary MACRO Core Technology for natural results. The product met clinical trial endpoints for safety and e...
09-10 10:45
Waldencast Reports Strategic Growth and New Acquisitions
Waldencast Acquisition Corp. ( ($WALD) ) has released its Q2 earnings. Here is ...
08-26 12:00
